Trastuzumab (Herceptin) Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Pipeline

Phase 2: 2Phase 3: 2

Top Sponsors

Sun Yat-sen University1
Shanghai Jiao Tong University School of Medicine1
Institut Curie1
Alliance for Clinical Trials in Oncology1

Indications

Breast Cancer4
Cancer4
Early-stage HER2+ Breast Cancer1
Unresectable Breast Cancer1
Early Stage Breast Carcinoma1

Other3 trials

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Phase 2

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

Phase 3

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

Phase 2

Phoenix, Arizona1 trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Cancer Center at Saint Joseph's

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.